REVIVe: Frailty, Rehabilitation, and Hospitalization Outcomes in Adult and Pediatric Survivors of COVID-19 (REVIVe)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05246098|
Recruitment Status : Recruiting
First Posted : February 18, 2022
Last Update Posted : February 8, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Background: Many adults and some children with COVID-19 become critically ill and need advanced life support in the Intensive Care Unit (ICU). Frailty is a medical condition of reduced function and health. Adults with frailty have a lower chance of surviving critical illness. The investigators are still learning about critically ill adults with COVID-19, and do not have much information on how frailty affects outcomes in critically ill children, with or without COVID-19. Rehabilitation can help survivors of COVID-19 by improving strength and improve quality of life (QOL).
Objectives: The main goal of this research study is to see if patients with frailty have a lower chance of surviving COVID-19 critical illness and more health problems after survival than patients without frailty. The investigators will also study the types of rehabilitation received by patients with COVID-19.
Methods: The investigators will include adults and children with COVID-19 who are admitted to the ICUs that participate in the study. The investigators will gather data about each patient, including before and during their illness.
Outcomes: The investigators will collect level of frailty, function, and types of therapy, or rehabilitation received by patients. In adults, The investigators are most interested in learning if frailty influences mortality, or death. In children, the investigators are most interested in whether children with COVID-19 critical illness are more likely to develop frailty. The investigators will also study post-hospital discharge location in survivors (e.g., home, rehabilitation).
Relevance: The COVID-19 pandemic is a global public health crisis. It is critical to understand how COVID-19 critical illness affects groups of people who are at higher risk, and the impact on outcomes that are important to patients, like functioning and QOL. The results will help policy makers plan post-hospital services for survivors, help healthcare workers understand the importance of rehabilitation practice for patients with COVID-19, and researchers develop treatments to improve QOL after COVID-19.
|Condition or disease|
|Respiratory Disease COVID-19 Viral Infection|
|Study Type :||Observational|
|Estimated Enrollment :||900 participants|
|Official Title:||REVIVe: Frailty, Rehabilitation, and Hospitalization Outcomes in Adult and Pediatric Survivors of COVID-19|
|Actual Study Start Date :||September 15, 2022|
|Estimated Primary Completion Date :||March 31, 2024|
|Estimated Study Completion Date :||October 1, 2024|
Adult survivors of severe acute respiratory syndrome (SARS) SARS-CoV-2 disease admitted to participating ICUs. Adults are defined as adults as greater than or equal to, 18 years old. We will include adults with a confirmed diagnosis of COVID-19.
Pediatric survivors of severe SARS-CoV-2 disease admitted to participating pediatric intensive care units (PICUs). The investigators define children as less than 18 years old. We will include pediatric patients with COVID-19 and those with multi-system inflammatory syndrome in children (MIS-C).
- Clinical Frailty Score (Adults) [ Time Frame: hospital discharge, 6-month hospital discharge ]Frailty
- Functional Status Score (Pediatrics) [ Time Frame: PICU discharge; 6-months post-PICU discharge ]Frailty (paediatrics)
- Katz activities of daily living (ADL; adults) [ Time Frame: hospital discharge, approximately 28 days after enrolment ]Physical Functional
- EQ5D-5L (EuroQoL; Adults) [ Time Frame: hospital discharge, approximately 28 days after enrolment; 6-month hospital discharge ]Physical Functional
- COVID-19 Yorkshire Rehab Screen [ Time Frame: 6-months post-hospital discharge ]Physical function; cognition; quality of life; disease symptoms
- Pediatric Quality of Life Inventory (PedQL) - Multidimensional Fatigue Scale [ Time Frame: 6-months post-PICU discharge ]Quality of Life; Each item is measured on a 5 point Likert scale with 0 indicating never and 4 indicating almost always.The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 3=25, and 4=0. A higher score indicates better health-related quality of life.
- Pediatric Quality of Life Inventory (PedQL) - General Well-being Scale [ Time Frame: 6-months post-PICU discharge ]Quality of Life; Each item is measured on a 5 point Likert scale with 0 indicating never and 4 indicating almost always.The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 3=25, and 4=0. A higher score indicates better health-related quality of life.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Months and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Adult and pediatric survivors of severe SARS-CoV-2 disease admitted to participating intensive care units (ICUs) and PICUs. The investigators define children as less than, and adults as greater than or equal to, 18 years old, respectively. The investigators will include adults with a confirmed diagnosis of COVID-19. The investigators will include pediatric patients with COVID-19 and those with MIS-C.
- The investigators will exclude patients who were admitted to ICU for <24 hours or did not receive at least one of the following therapeutic life support interventions: mechanical ventilation (e.g., invasive, non-invasive, high flow nasal cannula), vasoactive medications (vasopressors or inotropes), or acute renal replacement therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05246098
|Contact: Geoff Strong, PT, MS||905-522-1155 ext email@example.com|
|University of Alberta||Not yet recruiting|
|Edmonton, Alberta, Canada, T6G2B7|
|Contact: Oleksa Rewa, MD, MSc 780.231.3280 firstname.lastname@example.org|
|St. Joseph's Healthcare Intensive Care Unit||Recruiting|
|Hamilton, Ontario, Canada, L8N 4A6|
|Contact: Michelle Kho, PT, PhD email@example.com|
|McMaster Children's Hospital||Recruiting|
|Hamilton, Ontario, Canada, L8S 4K1|
|Contact: Karen Choong, MB, FRCP(C), MSc firstname.lastname@example.org|
|Principal Investigator:||Michelle E Kho, PT, PhD||McMaster University|
|Responsible Party:||McMaster University|
|Other Study ID Numbers:||
|First Posted:||February 18, 2022 Key Record Dates|
|Last Update Posted:||February 8, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections